What is the role of hydroxyurea in the pathophysiology of macrocytosis?

Updated: Dec 16, 2018
  • Author: Vincent E Herrin, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Hydroxyurea, an agent now commonly used to decrease the number of vaso-occlusive pain crises in patients with sickle cell disease, interferes with DNA synthesis, causing macrocytosis by which compliance with therapy may be monitored. Patient compliance with zidovudine, an agent used in the treatment of patients with HIV infection, may be monitored in the same way.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!